RARE - Ultragenyx Pharmaceutical GAAP EPS of -$2.16 beats by $0.02 revenue of $103.35M misses by $1.76M
- Ultragenyx Pharmaceutical press release ( NASDAQ: RARE ): Q4 GAAP EPS of -$2.16 beats by $0.02 .
- Revenue of $103.35M (+23.9% Y/Y) misses by $1.76M .
- 2023 expected Total Revenue guidance between $425 million to $450 million vs $426.25M consensus, Crysvita revenue of $325 million to $340 million, and Dojolvi revenue of $65 million to $75 million
For further details see:
Ultragenyx Pharmaceutical GAAP EPS of -$2.16 beats by $0.02, revenue of $103.35M misses by $1.76M